I'm not convinced progression free survival in this trial will be viewed as success. The most recent trial showed progression free survival quite clearly, albeit a small cohort. This wasn't enough to attract Elanco.
This trial aims to do much better and hopefully show regression to a greater or lesser degree in the dogs. Perhaps 8 dogs showing 20 to 70% regression would be convincing enough to a partner, because 6 or 7 dogs with progression free survival wasn't.
Ann: Appendix 4C and Quarterly Update, page-64
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.24M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $244.3K | 1.244M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 257206 | 7 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |